felin
infecti
periton
devast
fatal
diseas
domest
cat
caus
pathogen
mutant
viru
deriv
ubiquit
felin
enter
coronaviru
fecv
infect
fecv
gener
subclin
littl
known
mucos
immun
respons
control
elimin
viru
investig
mucos
immun
respons
fecv
endem
infect
breed
coloni
sevenmonth
period
thirtythre
cat
group
accord
fecv
seroposit
fecal
viru
shed
quiescent
convalesc
activ
infect
group
blood
fecal
sampl
colon
biopsi
collect
assess
mucos
system
immunolog
virolog
profil
result
show
cat
activ
fecv
infect
strong
system
igg
mucos
iga
respons
wane
viru
clearanc
signific
fecvspecif
mucos
cell
respons
detect
three
group
shift
toward
inflammatori
state
mucosa
suggest
increas
express
howev
histolog
abnorm
observ
shift
lymphocyt
subpopul
phenotyp
prolifer
note
togeth
result
suggest
control
fecv
mediat
humor
mucos
system
respons
perturb
primari
reservoir
organ
colon
minim
felin
infecti
periton
remain
intract
regard
diagnosi
treatment
prevent
review
gener
accept
felin
infecti
periton
viru
fipv
emerg
individu
cat
due
mutat
replic
felin
enter
coronaviru
fecv
fecv
mucos
transmit
replic
greatest
level
intestin
tract
commonli
persist
colon
epithelium
cat
abl
control
fecv
replic
elimin
infect
other
remain
infect
intermitt
persist
viru
shedder
addit
immun
fecv
lifelong
reinfect
occur
fecv
continu
churn
cat
popul
particularli
within
shelter
breed
coloni
cycl
repeat
exposur
infect
shed
within
fecvinfect
cat
combin
high
viru
replic
high
error
rate
rna
replic
result
innumer
mutat
mutat
occur
allow
viru
escap
immun
surveil
effici
infect
replic
monocyt
system
spread
fatal
fip
may
occur
vaccin
strategi
target
mutant
fipv
approach
ineffect
case
result
acceler
diseas
result
antibodydepend
enhanc
infect
review
date
attempt
control
sourc
fipcaus
mutant
viru
fecv
replic
excel
epidemiolog
studi
character
shed
transmiss
fecv
within
popul
fecv
circul
within
cat
popul
epidemiolog
character
repeat
infect
persist
shed
carrier
state
fecv
highli
contagi
shown
pedersen
et
al
fecvneg
cat
infect
within
one
week
introduct
anim
shelter
addit
time
enter
shelter
cat
alreadi
shed
fecv
level
shed
increas
fold
first
week
like
secondari
stress
associ
shelter
admiss
high
incid
infect
combin
massiv
viru
replic
greatli
enhanc
likelihood
mutant
viru
emerg
immunolog
respons
fipv
extens
studi
less
known
respons
fecv
particularli
intestin
mucosa
studi
coloni
cohous
cat
endem
fecv
seven
month
blood
fece
colon
biopsi
collect
establish
relationship
viru
control
mucos
system
immun
respons
result
show
mucos
iga
system
igg
associ
clearanc
viru
infect
cellmedi
immun
respons
detect
humor
respons
wane
rapidli
viru
clear
minim
structur
function
perturb
could
demonstr
colon
result
suggest
control
fecv
intestin
mucosa
might
achiev
vaccineinduc
humor
respons
goal
disrupt
endem
persist
fecv
cat
popul
reduc
chanc
fipv
emerg
individu
cat
care
accord
associ
assess
laboratori
anim
care
standard
approv
colorado
state
univers
institut
anim
care
use
committe
protocol
approv
juli
thirtythre
domest
shorthair
cat
maintain
specif
pathogenfre
spf
breed
coloni
colorado
state
univers
use
studi
cat
rang
year
age
includ
intact
femal
neuter
male
intact
male
coloni
known
circul
felin
coronaviru
fcov
base
seroposit
sporad
occurr
fip
sinc
establish
coloni
genom
circul
viru
sequenc
shown
serotyp
cat
offspr
coloni
mate
queen
individu
hous
prior
parturit
offspr
introduc
coloni
reach
breed
age
cat
group
hous
except
intact
male
hous
togeth
run
room
cat
day
colonoscopi
design
time
fecal
sampl
blood
collect
experiment
month
fecal
sampl
collect
litter
box
cat
temporarili
hous
individu
store
c
whole
blood
peripher
blood
mononuclear
cell
pbmc
plasma
isol
complet
blood
count
cbc
leukocyt
differenti
collect
vacutain
tube
contain
ethylenediaminetetraacet
acid
bd
franklin
lake
nj
usa
blood
serum
chemistri
collect
serum
vacutain
tube
pbmc
isol
centrifug
blood
milliporesigma
st
loui
mo
usa
pellet
store
c
plasma
isol
centrifug
g
min
aliquot
submit
full
chemistri
panel
frozen
c
cbc
leukocyt
differenti
full
serum
chemistri
panel
perform
colorado
state
univers
clinic
patholog
laboratori
colonoscopi
biopsi
pinch
biopsi
perform
month
gener
ga
anesthesia
overnight
fast
colon
biopsi
tissu
collect
formalin
histolog
immunohistochemistri
ihc
rnalat
rna
extract
rpmi
medium
penicillinstreptomycin
ge
healthcar
life
scienc
pittsburgh
pa
usa
gentamicin
milliporesigma
lymphocyt
isol
colon
biopsi
sampl
process
use
modif
previous
describ
protocol
briefli
endoscop
biopsi
digest
ml
digest
medium
consist
rpmi
without
lglutamin
corn
tewksburi
usa
ad
penicillinstreptomycin
ge
healthcar
life
scienc
liberas
dl
milliporesigma
mgml
dnase
grade
ii
milliporesigma
min
c
tissu
pass
steril
needl
time
easystrain
greiner
bioon
monro
nc
usa
larg
piec
undigest
tissu
return
c
min
addit
ml
fresh
digest
medium
process
repeat
twice
total
digest
step
three
cell
suspens
combin
pass
easystrain
greiner
bioon
wash
lbt
medium
rpmi
medium
supplement
fetal
bovin
serum
mm
hepe
mm
sodium
pyruv
mm
lglutamin
iu
penicillinml
streptomycinml
filter
falcon
tube
cell
strainer
cap
corn
live
nucleat
cell
count
use
viastain
aopi
stain
solut
cellomet
auto
nexcelom
bioscienc
lawrenc
usa
accord
manufactur
direct
approxim
mucos
lymphocyt
use
flow
cytometr
analysi
standard
stain
protocol
use
previous
describ
briefli
cell
block
proteasefre
bovin
serum
albumin
equitechbio
kerrvil
tx
stain
follow
antibodi
mous
anticat
clone
dean
et
al
unpublish
result
goat
antimous
conjug
southernbiotech
birmingham
al
usa
mous
anticat
conjug
fitc
clone
southernbiotech
mous
anticat
conjug
apc
clone
clinic
immunolog
laboratori
ncsu
raleigh
nc
usa
rat
antimous
conjug
percp
clone
biolegend
san
diego
ca
usa
cell
wash
treat
fixationpermeabil
solut
kit
bd
bioscienc
san
jose
ca
usa
wash
cell
stain
intracellularli
mous
antihuman
conjug
pe
bd
bioscienc
least
cell
analyz
use
gallio
flow
cytomet
beckman
coulter
indianapoli
usa
data
analysi
complet
use
flowjo
softwar
version
tree
star
ashland
usa
fcovspecif
igg
determin
use
commerci
avail
kit
felin
infecti
periton
viru
antibodi
test
kit
ivd
technolog
santa
ana
ca
usa
accord
manufactur
instruct
fecal
sampl
thaw
ice
portion
transfer
tube
weigh
goat
serum
equitechbio
proteasearrest
gbioscienc
st
loui
mo
usa
pb
ad
ml
per
mg
fece
sampl
homogen
min
ms
fastprep
instrument
mp
biomed
irvin
ca
usa
centrifug
min
g
aliquot
supernat
store
c
microlon
high
bind
plate
greiner
bioon
coat
overnight
c
goat
anticat
iga
bethyl
montgomeri
tx
usa
carbonatebicarbon
buffer
ph
coat
solut
replac
nonfat
dri
milk
coat
buffer
hour
c
wash
phosphat
buffer
salin
pbst
use
elisa
elispot
wash
step
fecal
supernat
felin
refer
serum
bethyl
serial
dilut
pbst
nonfat
dri
milk
goat
serum
ad
duplic
incub
c
h
plate
wash
time
goat
anticat
iga
bethyl
ad
h
c
wash
sureblu
reserv
tmb
microwel
peroxidas
substrat
seracar
milford
usa
ad
min
room
temperatur
rt
develop
stop
n
hcl
absorb
measur
nm
minu
background
measur
nm
synergi
micropl
reader
softwar
version
biotek
winooski
vt
usa
standard
curv
gener
refer
serum
well
use
microlon
high
bind
plate
greiner
bioon
coat
overnight
c
felin
infecti
periton
viru
antigen
ivd
technolog
pb
ph
coat
solut
replac
nonfat
dri
milk
pb
h
rt
plate
wash
time
pbst
min
soak
wash
fecal
extract
prepar
total
iga
elisa
posit
refer
sampl
serial
dilut
nonfat
dri
milk
normal
goat
serum
pbst
ad
per
well
duplic
plate
incub
c
h
wash
time
min
soak
wash
goat
anticat
iga
bethyl
ad
h
c
wash
sureblu
reserv
tmb
substrat
ad
min
rt
develop
stop
n
hcl
absorb
measur
nm
minu
background
measur
nm
fecal
sampl
thaw
ice
portion
transfer
tube
weigh
steril
salin
ad
ml
per
mg
fece
sampl
homogen
min
msec
fastprep
instrument
mp
biomed
irvin
ca
usa
centrifug
min
g
rna
extract
supernat
qiaamp
viral
rna
mini
kit
qiagen
germantown
md
usa
accord
manufactur
protocol
volum
supernat
buffer
avl
ethanol
rna
elut
ave
buffer
murin
rnase
inhibitor
new
england
biolab
ipswich
ca
usa
ad
rna
store
c
bufferonli
extract
includ
extract
batch
rna
extract
colon
biopsi
tissu
use
rneasi
powerlyz
tissu
cell
kit
per
manufactur
protocol
qiagen
briefli
tissu
homogen
two
cycl
ms
fastprep
oncolumn
treatment
rnasefre
dnase
includ
rna
extract
pbmc
use
rneasi
mini
kit
includ
qiashredd
rnasefre
dnase
treatment
qiagen
rnase
inhibitor
ad
elut
rna
storag
c
rna
quantifi
qubit
rna
br
assay
kit
thermo
fisher
scientif
waltham
usa
qualiti
assess
spectrophotometri
rna
high
sensit
screentap
assay
agil
santa
clara
ca
usa
bufferonli
extract
includ
tissu
pbmc
extract
batch
rna
analyz
presenc
fcov
rna
realtim
rtpcr
rtpcr
amplif
wellconserv
region
membran
nucleocapsid
gene
use
primer
nm
probe
sequenc
nm
ib
fqlabel
integr
dna
technolog
coralvil
ia
usa
previous
describ
luna
univers
probe
onestep
rtpcr
reagent
new
england
biolab
sampl
fecal
rna
ng
colon
pbmc
rna
run
triplic
reaction
white
pcr
plate
biorad
hercul
ca
usa
use
biorad
instrument
follow
cycl
condit
revers
transcript
c
min
initi
denatur
c
min
amplif
cycl
c
c
final
extens
c
min
serial
dilut
fcovposit
rna
includ
plate
qualiti
control
fcov
rna
detect
bufferonli
extract
control
notempl
control
includ
plate
rtpcr
reaction
carri
fcov
ng
colon
rna
primer
probe
sequenc
previous
publish
primer
forward
tggctcctgggacaacttc
revers
tcctcggtagttgggcatcc
probe
tcccatcactgctgctgctgctct
probe
ib
fqlabel
idt
addit
control
includ
nort
reaction
sampl
primerprob
set
realtim
intern
control
rna
reaction
primerdesign
ltd
plymouth
meet
pa
usa
sampl
inhibitor
analysi
rtpcr
inhibit
detect
multiscreenip
plate
milliporesigma
prewet
ethanol
wash
time
steril
pb
incub
overnight
c
goat
anticat
iga
bethyl
dilut
pb
pb
without
antibodi
neg
control
plate
wash
block
h
rt
lbt
medium
cellswel
total
iga
coat
iga
pb
cellswel
fcov
iga
igaco
well
pb
well
lbt
ad
incub
h
c
co
plate
wash
time
pb
time
pbst
addit
detect
reagent
dilut
fetal
bovin
serumpb
overnight
incub
c
total
iga
detect
reagent
goat
anticat
igahrp
bethyl
fcov
iga
detect
reagent
fipv
antigen
ivd
biotinyl
use
chromalink
biotin
label
kit
trilink
biotechnolog
san
diego
ca
usa
incub
plate
wash
time
pbst
incub
pierc
streptavidinhrp
thermo
fisher
scientif
h
rt
assay
plate
wash
time
pbst
time
pb
spot
develop
use
tmb
substrat
elispot
mabtech
inc
cincinnati
oh
follow
wash
ultrapur
water
dri
plate
scan
immunospot
analyz
ctl
cincinnati
oh
usa
spot
count
use
immunospot
softwar
version
ctl
captur
detect
antibodi
felin
develop
modul
r
system
use
multiscreenip
plate
milliporesigma
quantifi
mucos
lymphocyt
stimul
phorbol
pma
ngml
lc
laboratori
woburn
ionomycin
ngml
lc
laboratori
fipv
antigen
ivd
technolog
santa
ana
ca
usa
previous
describ
protocol
modifi
use
cellswel
pmaionomycin
cellswel
fipv
antigen
incub
h
c
co
plate
scan
immunospot
analyz
analysi
perform
ctl
formalinfix
tissu
process
stain
hematoxylin
eosin
fcov
antigen
colorado
state
univers
veterinari
diagnost
laboratori
briefli
fcov
immunohistochemistri
perform
use
mous
antifelin
coronaviru
primari
clone
biorad
powervis
polyap
antimous
igg
secondari
leica
microsystem
inc
buffalo
grove
il
heatinduc
epitop
retriev
leica
bondiii
ihc
autom
stainer
use
bond
epitop
retriev
solut
min
label
perform
autom
stain
platform
fast
red
use
chromogen
slide
counterstain
hematoxylin
analys
perform
opensourc
program
r
version
logtransform
valu
variabl
evalu
separ
use
linear
model
variabl
zero
valu
small
constant
ad
prior
logtransform
base
rang
valu
residu
model
test
normal
homoskedast
none
found
violat
assumpt
group
mean
confid
interv
extract
model
use
packag
emmean
version
data
handl
packag
dplyr
version
plot
creat
use
packag
version
fcov
infect
statu
cat
includ
studi
determin
elisa
fcovspecif
plasma
igg
rtpcr
fecal
viru
rna
base
data
cat
group
analysi
tabl
group
cat
n
averag
age
yr
rang
yr
fcov
seroneg
viru
neg
throughout
studi
given
cat
gang
hous
like
expos
fcov
possibl
infect
point
prior
studi
period
group
cat
n
averag
age
yr
rang
yr
seroposit
time
colonoscopi
never
test
posit
fecal
tissu
colon
biopsi
blood
viru
group
cat
n
averag
age
yr
rang
yr
seroposit
also
fecal
viru
posit
timepoint
andor
month
eight
nine
group
cat
control
viru
shed
within
three
month
start
studi
cat
uncontrol
viru
shed
remain
fecal
viru
posit
throughout
studi
period
colon
biopsi
also
viru
posit
serolog
statu
rtpcr
result
group
shown
tabl
group
anticip
repres
differ
immunolog
state
might
identifi
correl
protect
fecv
group
cat
repres
immun
immun
quiescent
state
group
cat
repres
convalesc
phase
immun
respons
fortuit
collect
colon
biopsi
eight
cat
group
near
time
viru
replic
control
presum
provid
snapshot
success
mucos
immun
respons
viru
averag
time
observ
viru
shed
cat
ultim
control
viru
replic
month
averag
time
seroposit
viru
replic
control
month
data
reveal
less
viru
infect
kinet
sinc
studi
natur
infect
cat
actual
time
infect
known
conclud
system
immun
respons
wane
rapidli
viru
clear
cat
seroposit
time
colon
biopsi
group
seroneg
end
studi
day
colonoscopi
biopsi
complet
blood
count
full
serum
chemistri
panel
perform
abnorm
identifi
individu
anim
differ
observ
group
tabl
pbmc
analyz
fcov
rtpcr
neg
result
consist
subclin
natur
fecv
infect
sporad
viremia
total
fecal
iga
measur
elisa
trend
group
cat
higher
level
differ
reach
signific
figur
fcovspecif
fecal
iga
significantli
higher
p
cat
activ
shed
viru
compar
either
group
group
figur
result
suggest
role
mucos
iga
control
clearanc
fecv
infect
total
fecal
iga
measur
elisa
trend
group
cat
higher
level
differ
reach
signific
figur
fcovspecif
fecal
iga
significantli
higher
p
cat
activ
shed
viru
compar
either
group
group
figur
result
suggest
role
mucos
iga
control
clearanc
fecv
infect
colon
pinch
biopsi
collect
histopatholog
stain
fcov
antigen
immunohistochemistri
histopatholog
abnorm
note
conclus
posit
stain
fcov
antigen
observ
cat
posit
neg
control
tissu
stain
expect
tissueassoci
viru
detect
rtpcr
three
nine
cat
group
cat
also
posit
fecal
viru
tabl
lymphocyt
isol
colon
pinch
biopsi
phenotyp
prolifer
analysi
percentag
cell
cell
b
cell
determin
percentag
popul
measur
assess
prolifer
tabl
lymphocyt
biopsi
repres
intraepitheli
lymphocyt
iel
lamina
propria
lymphocyt
lpl
lpl
numer
typic
mix
iel
predominantli
cat
mice
macaqu
human
signific
differ
group
indic
activ
fecv
replic
group
cat
result
phenotyp
shift
increas
lymphocyt
prolifer
colon
mucosa
differ
group
percentag
combin
n
provid
refer
rang
futur
studi
examin
colon
biopsi
sinc
analysi
previous
report
colon
pinch
biopsi
collect
histopatholog
stain
fcov
antigen
immunohistochemistri
histopatholog
abnorm
note
conclus
posit
stain
fcov
antigen
observ
cat
posit
neg
control
tissu
stain
expect
tissueassoci
viru
detect
rtpcr
three
nine
cat
group
cat
also
posit
fecal
viru
tabl
lymphocyt
isol
colon
pinch
biopsi
phenotyp
prolifer
analysi
percentag
cell
cell
b
cell
determin
percentag
popul
measur
assess
prolifer
tabl
lymphocyt
biopsi
repres
intraepitheli
lymphocyt
iel
lamina
propria
lymphocyt
lpl
lpl
numer
typic
mix
iel
predominantli
cat
mice
macaqu
human
signific
differ
group
indic
activ
fecv
replic
group
cat
result
phenotyp
shift
increas
lymphocyt
prolifer
colon
mucosa
differ
group
percentag
combin
n
provid
refer
rang
futur
studi
examin
colon
biopsi
sinc
analysi
previous
report
elispot
assay
undertaken
lymphocyt
isol
colon
biopsi
determin
total
number
igaproduc
cell
number
fcovspecif
igaproduc
cell
similar
fecal
iga
signific
differ
observ
number
igaproduc
cell
figur
number
fcovspecif
igaproduc
cell
significantli
greater
p
group
compar
either
group
group
figur
fecal
iga
result
appear
fecv
replic
induc
mucos
humor
respons
may
import
limit
viru
replic
elispot
assay
undertaken
lymphocyt
isol
colon
biopsi
determin
total
number
igaproduc
cell
number
fcovspecif
igaproduc
cell
similar
fecal
iga
signific
differ
observ
number
igaproduc
cell
figur
number
fcovspecif
igaproduc
cell
significantli
greater
p
group
compar
either
group
group
figur
fecal
iga
result
appear
fecv
replic
induc
mucos
humor
respons
may
import
limit
viru
replic
total
number
colon
lymphocyt
potenti
produc
determin
stimul
pmaionomycin
total
number
fcovspecif
cell
determin
restimul
viral
antigen
signific
differ
group
capac
antigenspecif
product
figur
result
suggest
cellmedi
control
fecv
infect
unlik
play
role
colon
mucosa
mean
assess
state
cell
balanc
inflamm
regul
transcript
ratio
determin
rtpcr
group
cat
significantli
higher
ratio
compar
group
indic
overal
tendenc
toward
inflamm
figur
total
number
colon
lymphocyt
potenti
produc
determin
stimul
pmaionomycin
total
number
fcovspecif
cell
determin
restimul
viral
antigen
signific
differ
group
capac
antigenspecif
product
figur
result
suggest
cellmedi
control
fecv
infect
unlik
play
role
colon
mucosa
mean
assess
state
cell
balanc
inflamm
regul
transcript
ratio
determin
rtpcr
group
cat
significantli
higher
ratio
compar
group
indic
overal
tendenc
toward
inflamm
figur
felin
coronaviru
infect
present
virolog
immunolog
conundrum
rel
innocu
enter
pathogen
induc
modest
immun
respons
evolv
felin
coronaviru
infect
present
virolog
immunolog
conundrum
rel
innocu
enter
pathogen
induc
modest
immun
respons
evolv
felin
coronaviru
infect
present
virolog
immunolog
conundrum
rel
innocu
enter
pathogen
induc
modest
immun
respons
evolv
uncontrol
system
pathogen
drive
destruct
immunolog
storm
wellsupport
hypothesi
emerg
viral
mutant
expand
host
cell
rang
permit
infect
effici
replic
monocytesmacrophag
well
system
spread
viru
drive
immunopatholog
pathway
includ
lymphocyt
apoptosi
antibodi
complex
deposit
granulomat
inflamm
dramat
immun
respons
associ
fip
extens
studi
much
less
known
mucos
immun
respons
fecv
success
control
fecv
limit
viral
replic
enter
patholog
review
took
advantag
close
coloni
spf
cat
endem
serotyp
fcov
character
immun
respons
associ
viru
control
sinc
colon
primari
reservoir
site
replic
fecv
colon
biopsi
logic
conveni
mucos
immun
respons
evalu
distribut
enrol
cat
base
combin
serolog
fecal
viru
statu
similar
previou
report
allow
direct
comparison
quiescent
convalesc
activ
infect
cat
fortuit
eight
nine
cat
posit
fecal
viru
shed
control
replic
shortli
colon
biopsi
thu
immun
profil
observ
tissu
might
provid
correl
protect
fecv
cat
significantli
elev
mucos
iga
along
system
igg
fcov
measur
mucos
cell
respons
base
result
appear
fecv
control
mediat
antibodi
respons
fcovspecif
iga
significantli
elev
cat
activ
shed
viru
measur
fecal
elisa
quantif
igaproduc
cell
colon
mucosa
suggest
secretori
iga
siga
may
play
key
role
prevent
immunopathogenesi
fecv
infect
siga
abundantli
produc
antibodi
isotyp
bodi
highli
resist
proteolysi
engend
stabil
harsh
environ
intestin
tract
siga
mucophil
accumul
greater
concentr
mucu
layer
cover
intestin
epithelium
therefor
stand
first
adapt
immun
defens
mucos
pathogen
effector
function
siga
includ
viru
neutral
immun
exclus
intestin
lumen
intracellular
inactiv
virus
remov
antigen
lamina
propria
iga
also
demonstr
review
addit
contrast
igg
iga
activ
complement
prevent
inflamm
tissu
damag
infect
review
though
studi
need
gener
lack
immun
activ
measur
studi
combin
effect
control
viral
replic
suggest
key
role
siga
subclin
fecv
infect
fecv
infect
result
remark
clinic
immunolog
perturb
despit
astound
level
viru
replic
observ
abnorm
serum
chemistri
profil
cbc
group
cat
likewis
cellassoci
viru
detect
blood
even
though
system
dissemin
fecv
infect
well
describ
may
miss
window
viremia
cat
verg
control
replic
gastrointestin
tract
similarli
fcov
antigen
demonstr
colon
biopsi
three
nine
cat
posit
viral
rna
biopsi
tissu
also
suggest
wane
infect
perhap
low
sensit
assay
given
small
amount
tissu
singl
mm
biopsi
avail
analysi
differ
note
mucos
lymphocyt
phenotyp
percentag
prolifer
group
cat
consist
lack
inflamm
histolog
colon
inflamm
multifoc
possibl
colon
biopsi
evalu
repres
inflammatori
state
elsewher
colon
featur
confirm
overal
pictur
rel
benign
enter
viral
infect
despit
robust
viral
replic
assess
cell
mediat
immun
respons
measur
constitut
fcovspecif
product
differ
observ
group
suggest
cellular
sourc
includ
nk
cell
nkt
cell
cell
overrepres
colon
mucosa
fecvshed
cat
furthermor
lack
differ
cell
stimul
fcov
antigen
suggest
lack
cytotox
cell
adapt
respons
small
number
colon
lymphocyt
avail
immunophenotyp
limit
analysi
rel
low
number
cell
surpris
previous
report
phenotyp
intraepitheli
lamina
propria
lymphocyt
iel
lpl
respect
small
intestin
cat
small
intestin
iel
predominantli
major
lpl
cell
method
use
harvest
iel
lpl
togeth
phenotyp
colon
lymphocyt
previous
report
cat
mice
human
cell
predomin
iel
lpl
colon
despit
domin
cell
mice
human
low
percentag
cell
colon
mucosa
cat
seem
unusu
could
artifact
tissu
process
antibodi
select
howev
use
method
reagent
previous
valid
analysi
lymphocyt
small
intestin
work
requir
confirm
result
function
character
felin
colon
lymphocyt
gain
understand
cell
bia
colon
mucosa
measur
mrna
indic
cell
inflamm
indic
cell
neg
regul
result
show
increas
mucos
mrna
suggest
modest
shift
toward
inflammatori
environ
mani
caveat
approach
proxi
evalu
regulatori
cell
treg
small
tissu
sampl
size
lack
felinespecif
reagent
identifi
start
studi
limit
option
interestingli
crossreact
antibodi
recent
report
use
assess
fipassoci
uveiti
along
exist
reagent
protocol
evalu
felin
treg
flow
cytometri
futur
studi
directli
assess
rel
presenc
treg
hypothes
fail
cell
respons
distinguish
diseas
resist
progress
fip
care
investig
recent
studi
character
cell
respons
cat
primari
fipv
infect
survivor
primari
infect
receiv
secondari
challeng
viru
cell
respons
appar
acut
phase
primari
infect
emerg
secondari
infect
correl
protect
fipv
progress
clear
messag
type
fcov
infect
induc
robust
cell
respons
regardless
whether
isol
associ
enter
infect
fip
sever
studi
character
variou
cours
fecv
shed
transient
intermitt
persist
cat
correl
system
antibodi
respons
rapid
declin
antibodi
titer
control
fecv
replic
commonli
observ
case
cat
studi
lack
durabl
presumpt
protect
antibodi
respons
underli
potenti
repeat
reinfect
also
repres
challeng
develop
fcov
vaccin
hostpathogen
balanc
exist
cat
fcov
viru
rare
pathogen
mild
infect
elicit
lifelong
immun
therebi
allow
perpetu
endem
state
cat
popul
occasion
emerg
highli
pathogen
fipv
success
immun
fcov
like
requir
induct
robust
cell
respons
drive
establish
b
cell
memori
longerliv
plasma
cell
also
creat
cellmedi
immun
safeti
net
event
fipv
emerg
intrigu
consid
target
fecv
mean
prevent
fipv
emerg
associ
fatal
diseas
seem
reason
prevent
reduc
fecv
replic
would
reduc
chanc
fipv
emerg
antifecv
antibodi
system
mucos
correl
fecv
control
elimin
oral
deliv
vaccin
target
protect
fcov
epitop
may
provid
protect
particularli
highdens
stress
environ
associ
shelter
coloni
success
vaccin
would
avoid
pitfal
antibodydepend
enhanc
associ
antispik
protein
igg
identif
protect
epitop
like
requir
map
clone
felin
antifecv
antibodi
develop
vitro
assay
capabl
test
relev
effector
function
viru
exclus
neutral
context
intestin
mucosa
virtual
find
regard
fcov
infect
cat
requir
caveat
dr
jekyl
fecv
realli
quit
brilliant
caus
minim
pathogen
enter
infect
result
massiv
viru
replic
ensur
persist
viru
cat
popul
mr
hyde
fipv
murder
immunopath
invari
kill
immun
respons
turn
host
critic
keep
mind
deal
dr
jekyl
mr
hyde
differ
approach
may
requir
prevent
diagnosi
treatment
one
versu
regardless
viru
remain
fundament
character
first
time
mucos
humor
cellular
respons
fecv
suggest
mucos
iga
system
igg
respons
necessari
viru
control
given
lack
demonstr
cellmedi
immun
respons
signific
addit
work
requir
character
viral
target
antibodi
effector
function
need
success
vaccin
fcov
success
immun
strategi
also
requir
induct
robust
cell
respons
follow
avail
onlin
http
tabl
serum
chemistri
hematolog
result
